The Evolving Drug Safety Landscape: Implications for Pharma
01 December
A webinar outlining the implications of the changing regulatory landscape on the industry in the short to medium term - and what could be considered in developing strategies to increase the safety profile of products - is being hosted by ICON on Wednesday 9 December at 4 pm GMT. 'Politics, Regulators and Clinical Research' will feature panelists including ICON's Suzanne Gagnon, IMS Health's Nigel Burrows and Christopher-Paul Milne, associate director of the Tufts Center for the Study of Drug Development.
Senior pharma executives involved in the drug safety or/and outsourcing strategies for their organization are invited to attend the webinar, which will discuss "what the political reforms of today mean for clinical research tomorrow"; "how recently published draft regulations from the FDA (and the expected EMEA guidelines) address drug safety and what they mean for your organization"; and "what innovative strategies pharma/biotech companies can do to continue to deliver treatments in a cost effective way."
Click here to register for this event.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
